Caption Management’s UroGen Pharma URGN Stock Holding History

Caption Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,124	Closed	-$74.2K	–	2073
2026 Q1	$74.2K	Buy	+4,124	New	+$82.7K	﹤0.01%	1409

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Caption Management's URGN Position: Q2 2026 in Review

Caption Management sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 4,124 shares — an estimated $74.2K sold.

Caption Management first reported a position in URGN in Q1 2026 and held it in 1 quarter. The position peaked at $74.2K in Q1 2026. 174 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Caption Management reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
Caption Management sold 4,124 UroGen Pharma shares in Q2 2026, an estimated $74.2K.
Caption Management first reported a position in UroGen Pharma in Q1 2026 and held it in 1 quarter.
Caption Management's UroGen Pharma position peaked at $74.2K in Q1 2026.
174 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.